Immunome Inc. financial data

Symbol
IMNM on Nasdaq
Industry
Pharmaceutical Preparations
Location
18702 N. Creek Parkway, Suite 100, Bothell, WA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 721 % +245%
Debt-to-equity 28.9 % -77.6%
Return On Equity -158 % +5%
Return On Assets -122 % -68.8%
Operating Margin -2.52K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +392%
Common Stock, Shares, Outstanding 60M shares +392%
Entity Public Float 75.5M USD +121%
Common Stock, Value, Issued 6K USD +500%
Weighted Average Number of Shares Outstanding, Basic 59.9M shares +391%
Weighted Average Number of Shares Outstanding, Diluted 59.9M shares +391%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.8M USD -44.5%
Research and Development Expense 57.9M USD +203%
General and Administrative Expense 25.4M USD +80.3%
Operating Income (Loss) -272M USD -922%
Net Income (Loss) Attributable to Parent -263M USD -904%
Earnings Per Share, Basic -7.68 USD/shares -249%
Earnings Per Share, Diluted -7.68 USD/shares -249%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 165M USD +330%
Assets, Current 284M USD +619%
Property, Plant and Equipment, Net 6.1M USD +407%
Operating Lease, Right-of-Use Asset 2.52M USD +1350%
Other Assets, Noncurrent 3.21M USD
Assets 296M USD +615%
Accounts Payable, Current 7.05M USD +90.5%
Employee-related Liabilities, Current 2.35M USD +159%
Contract with Customer, Liability, Current 12.6M USD -28.7%
Liabilities, Current 39.9M USD +51.2%
Contract with Customer, Liability, Noncurrent 2.21M USD -76.6%
Deferred Income Tax Liabilities, Net 378K USD +1119%
Operating Lease, Liability, Noncurrent 2.48M USD
Other Liabilities, Noncurrent 1.34M USD +2061%
Liabilities 42.4M USD +32%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -388M USD -209%
Stockholders' Equity Attributable to Parent 254M USD +2618%
Liabilities and Equity 296M USD +615%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.2M USD -146%
Net Cash Provided by (Used in) Financing Activities 219M USD +645326%
Net Cash Provided by (Used in) Investing Activities -37.2M USD -35024%
Common Stock, Shares Authorized 300M shares +50%
Common Stock, Shares, Issued 60M shares +392%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 171M USD +610%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 165M USD +330%
Deferred Tax Assets, Valuation Allowance 39.8M USD +30.1%
Deferred Tax Assets, Gross 40.2M USD +31.2%
Operating Lease, Liability 2.77M USD
Payments to Acquire Property, Plant, and Equipment 2.16M USD +1942%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.1M USD -550%
Lessee, Operating Lease, Liability, to be Paid 3.87M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 841K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 879K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 727K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 37K USD 0%
Additional Paid in Capital 642M USD +375%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 157K USD +67%
Deferred Tax Assets, Net of Valuation Allowance 378K USD +1119%
Share-based Payment Arrangement, Expense 9.35M USD +88.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%